Patients with advanced or metastatic HCC are usually only eligible to receive systemic therapy with chemotherapy, tyrosine kinase inhibitors (TKIs), or immune checkpoint inhibitors, such as programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors [2,8,9]. The gene discussed is CD274; the disease is hepatocellular carcinoma.